Compass Therapeutics, Inc. business relationships
Companies named in Compass Therapeutics, Inc.’s 10-K filed 2026-03-05, and public companies whose annual reports name Compass Therapeutics, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.7 / 10
- AI naming
- 12 / 100 Top 6% in its category
- Agent readiness
- 5 / 100
- AI adoption
- 0 / 100
Named in Compass Therapeutics, Inc.’s annual report 2
“The Company entered into a collaboration agreement with Adimab, LLC on October 16, 2014.” SEC filing
“Research and Development Collaboration and License Agreement, dated November 30, 2018, between Trigr Therapeutics, Inc. and ABL Bio Inc. (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q filed with the SEC on August 16, 2021)” SEC filing
Companies whose annual reports name Compass Therapeutics, Inc. 1
“...tumor indications, including, but not limited to, ivonescimab (Summit Therapeutics Inc.), pumitamig (co-developed by BioNTech SE and Bristol Myers Squibb), LM-299 (LaNova Medicines Ltd.; in-licensed by Merck), SSGJ-707 (3SBio Inc.; in-licensed by Pfizer), and CTX-10726 (Compass Therapeutics, Inc.).” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.